Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219)

Antimicrob Agents Chemother. 1996 Jan;40(1):47-9. doi: 10.1128/AAC.40.1.47.

Abstract

A single 200-mg oral dose of trovafloxacin (CP-99,219) was given to each of eight healthy male volunteers, and the concentrations of the drug were measured in plasma, cantharides-induced inflammatory fluid, and urine over the subsequent 36 h. The mean maximum concentration observed in plasma was 2.9 micrograms/ml at a mean time of 0.75 h postdose. The mean maximum concentration observed in inflammatory fluid was 1.2 micrograms/ml at 4.0 h postdose. The mean elimination half-life in plasma was 7.8 h. The overall penetration into inflammatory fluid was 64%, as assessed by determining the ratio of the area under the concentration-time curves. Recovery of the dose in urine within the first 36 h postdose was 5.0% of the administered dose. Our results indicate that trovafloxacin, at a dosage of 200 mg once or twice daily, should be adequate for the treatment of systemic infections caused by most common bacterial pathogens.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anti-Infective Agents / blood
  • Anti-Infective Agents / pharmacokinetics*
  • Anti-Infective Agents / urine
  • Blister / chemically induced
  • Blister / drug therapy
  • Blister / metabolism*
  • Drug Administration Schedule
  • Exudates and Transudates / metabolism
  • Fluoroquinolones*
  • Half-Life
  • Humans
  • Male
  • Naphthyridines / blood
  • Naphthyridines / pharmacokinetics*
  • Naphthyridines / urine

Substances

  • Anti-Infective Agents
  • Fluoroquinolones
  • Naphthyridines
  • trovafloxacin